aripiprazole has been researched along with glutamic acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, J; McCorvy, JD; Tan, L; Yan, W | 1 |
| Carlsson, A; Carlsson, ML; Nilsson, M | 1 |
| Wang, SJ; Yang, TT | 1 |
| Akaike, A; Izumi, Y; Kume, T; Matsuo, T; Sawada, H; Takada-Takatori, Y | 1 |
| Calcagno, E; Carli, M; Invernizzi, RW; Mainini, E; Mainolfi, P | 1 |
| Fernalld, R; Jordan, S; Kambayashi, J; Kikuchi, T; Koprivica, V; Murphy, JJ; Regardie, K; Wolff, C | 1 |
| Chadman, KK; Guariglia, SR; Yoo, JH | 1 |
| Argilli, E; Bonci, A; Madhavan, A; Whistler, JL | 1 |
| Abaei, A; Boeckers, TM; Fegert, JM; Hengerer, B; Nespoli, E; Rasche, V; Rizzo, F | 1 |
| Fukuyama, K; Hasegawa, T; Okada, M | 1 |
3 review(s) available for aripiprazole and glutamic acid
| Article | Year |
|---|---|
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Topics: Animals; Drug Discovery; Humans; Ligands; Receptors, G-Protein-Coupled; Signal Transduction; Structure-Activity Relationship | 2018 |
Schizophrenia: from dopamine to glutamate and back.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Mice; Piperazines; Piperidines; Quinolones; Schizophrenia | 2004 |
New directions in the treatment of autism spectrum disorders from animal model research.
Topics: Adolescent; Adolescent Behavior; Animals; Antipsychotic Agents; Aripiprazole; Brain; Central Nervous System Stimulants; Child; Child Behavior; Child Development Disorders, Pervasive; Child, Preschool; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Discovery; GluK2 Kainate Receptor; Glutamic Acid; Humans; Methylphenidate; Mice; Mice, Inbred C57BL; Oxytocin; Piperazines; Quinolones; Rats; Receptors, Kainic Acid; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 2012 |
7 other study(ies) available for aripiprazole and glutamic acid
| Article | Year |
|---|---|
Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia.
Topics: Animals; Aripiprazole; Dose-Response Relationship, Drug; Glutamic Acid; Humans; Male; Neuroprotective Agents; Piperazines; Prefrontal Cortex; Presynaptic Terminals; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia | 2008 |
Protective effect of aripiprazole against glutamate cytotoxicity in dopaminergic neurons of rat mesencephalic cultures.
Topics: Animals; Aripiprazole; Cell Survival; Cells, Cultured; Chromatography, High Pressure Liquid; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Embryo, Mammalian; Glutamic Acid; Mesencephalon; Neurons; Neuroprotective Agents; Piperazines; Quinolones; Rats; Time Factors | 2010 |
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Choice Behavior; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Haloperidol; Impulsive Behavior; Male; Microdialysis; Neuropsychological Tests; Olanzapine; Piperazines; Prefrontal Cortex; Quinolones; Rats; Reaction Time; Schizophrenia; Serotonin; Time Factors | 2011 |
Aripiprazole protects cortical neurons from glutamate toxicity.
Topics: Animals; Aripiprazole; Benzodiazepines; Cell Nucleus; Cerebral Cortex; Cytoprotection; Dopamine D2 Receptor Antagonists; Glutamic Acid; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Molecular Imaging; Neurons; Neuroprotective Agents; Olanzapine; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Risperidone; Serotonin 5-HT1 Receptor Antagonists; Signal Transduction; Tetrazolium Salts; Thiazoles | 2011 |
Loss of D2 dopamine receptor function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental area.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Carrier Proteins; Cocaine; Dopamine Uptake Inhibitors; Down-Regulation; Excitatory Postsynaptic Potentials; Female; Glutamic Acid; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neuronal Plasticity; Organ Culture Techniques; Piperazines; Quinolones; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials; Ventral Tegmental Area | 2013 |
Aripiprazole and Riluzole treatment alters behavior and neurometabolites in young ADHD rats: a longitudinal
Topics: Animals; Antipsychotic Agents; Aripiprazole; Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Brain; Disease Models, Animal; Glutamic Acid; Magnetic Resonance Spectroscopy; Male; Motor Activity; Neuroprotective Agents; Rats; Rats, Inbred WKY; Riluzole | 2017 |
Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission.
Topics: Acetylcysteine; Animals; Antiporters; Aripiprazole; Dizocilpine Maleate; Glutamic Acid; Male; Models, Biological; N-Methylaspartate; Perfusion; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thalamus | 2018 |